Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus
ML Ooi, AJ Drilling, S Morales, S Fong… - … –Head & Neck …, 2019 - jamanetwork.com
Importance Staphylococcus aureusinfections are associated with recalcitrant chronic
rhinosinusitis (CRS). The emerging threat of multidrug-resistantS aureusinfections has
revived interest in bacteriophage (phage) therapy. Objective To investigate the safety,
tolerability, and preliminary efficacy of ascending multiple intranasal doses of investigational
phage cocktail AB-SA01 in patients with recalcitrant CRS due toS aureus. Design, Setting,
and Participants This phase 1, first-in-humans, open-label clinical trial of multiple ascending …
rhinosinusitis (CRS). The emerging threat of multidrug-resistantS aureusinfections has
revived interest in bacteriophage (phage) therapy. Objective To investigate the safety,
tolerability, and preliminary efficacy of ascending multiple intranasal doses of investigational
phage cocktail AB-SA01 in patients with recalcitrant CRS due toS aureus. Design, Setting,
and Participants This phase 1, first-in-humans, open-label clinical trial of multiple ascending …
[PDF][PDF] Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus
OBJECTIVE To investigate the safety, tolerability, and preliminary efficacy of ascending
multiple intranasal doses of investigational phage cocktail AB-SA01 in patients with
recalcitrant CRS due to S aureus. DESIGN, SETTING, AND PARTICIPANTS This phase 1,
first-in-humans, open-label clinical trial of multiple ascending doses was conducted at a
single tertiary referral center from December 1, 2015, through September 30, 2016, with
follow-up completed on December 31, 2016. Patients with recalcitrant CRS (aged 18-70 …
multiple intranasal doses of investigational phage cocktail AB-SA01 in patients with
recalcitrant CRS due to S aureus. DESIGN, SETTING, AND PARTICIPANTS This phase 1,
first-in-humans, open-label clinical trial of multiple ascending doses was conducted at a
single tertiary referral center from December 1, 2015, through September 30, 2016, with
follow-up completed on December 31, 2016. Patients with recalcitrant CRS (aged 18-70 …
以上显示的是最相近的搜索结果。 查看全部搜索结果